Stroke, major bleeding, and mortality outcomes in warfarin users with atrial fibrillation and chronic kidney disease: A meta-analysis of observational studies

Chest

Volumn 149, Issue 4, 2016, Pages 951-959

  Dahal, Khagendra ^a   Kunwar, Sumit ^a   Rijal, Jharendra ^b   Schulman, Peter ^c   Lee, Juyong ^c  

^a UNIVERSITY OF NEW ENGLAND   (United States)

^b BROWN UNIVERSITY   (United States)

^c UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

Author keywords

Atrial fibrillation; Chronic kidney disease; Dialysis; Major bleeding; Mortality; Stroke; Warfarin

Indexed keywords

WARFARIN; ANTICOAGULANT AGENT;

ARTICLE; ATRIAL FIBRILLATION; BLEEDING; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; HUMAN; META ANALYSIS; MORTALITY; PRIORITY JOURNAL; PUBLISHING; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK BENEFIT ANALYSIS; RISK REDUCTION; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW; THROMBOEMBOLISM; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; CHEMICALLY INDUCED; CHRONIC KIDNEY FAILURE; COMPLICATION; KIDNEY FAILURE, CHRONIC; PROPORTIONAL HAZARDS MODEL; RENAL REPLACEMENT THERAPY; RISK ASSESSMENT; STROKE;

ANTICOAGULANTS; ATRIAL FIBRILLATION; HEMORRHAGE; HUMANS; KIDNEY FAILURE, CHRONIC; MORTALITY; PROPORTIONAL HAZARDS MODELS; RENAL INSUFFICIENCY, CHRONIC; RENAL REPLACEMENT THERAPY; RISK ASSESSMENT; STROKE; WARFARIN;

EID: 84964528878     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.15-1719     Document Type: Article

References (36)

1. Baber U, Howard VJ, Halperin JL, et al. Association of chronic kidney disease with atrial fibrillation among adults in the United States: REasons for Geographic and Racial Differences in Stroke (REGARDS) Study. Circ Arrhythm Electrophysiol. 2011;4(1):26-32.
2. Soliman EZ, Prineas RJ, Go AS, et al. Chronic kidney disease and prevalent atrial fibrillation: the Chronic Renal Insufficiency Cohort (CRIC). Am Heart J. 2010;159(6):1102-1107.
3. Zimmerman D, Sood MM, Rigatto C, Holden RM, Hiremath S, Clase CM. Systematic review and meta-analysis of incidence, prevalence and outcomes of atrial fibrillation in patients on dialysis. Nephrol Dial Transplant. 2012;27(10): 3816-3822.
4. Zeng WT, Sun XT, Tang K, et al. Risk of thromboembolic events in atrial fibrillation with chronic kidney disease. Stroke. 2015;46(1):157-163.
5. Hijazi Z, Hohnloser SH, Oldgren J, et al. Efficacy and safety of dabigatran compared with warfarin in relation to baseline renal function in patients with atrial fibrillation: a RE-LY (Randomized Evaluation of Long-term Anticoagulation Therapy) trial analysis. Circulation. 2014;129(9):961-970.
6. Hohnloser SH, Hijazi Z, Thomas L, et al. Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial. Eur Heart J. 2012;33(22):2821-2830.
7. Aguilar MI, Hart R. Oral anticoagulants for preventing stroke in patients with non-valvular atrial fibrillation and no previous history of stroke or transient ischemic attacks. Cochrane Database Syst Rev. 2005;(3):CD001927.
8. Marinigh R, Lane DA, Lip GY. Severe renal impairment and stroke prevention in atrial fibrillation: implications for thromboprophylaxis and bleeding risk. J Am Coll Cardiol. 2011;57(12):1339-1348.
9. Olesen JB, Lip GY, Kamper AL, et al. Stroke and bleeding in atrial fibrillation with chronic kidney disease. N Engl J Med. 2012;367(7):625-635.
10. Shah M, Avgil Tsadok M, Jackevicius CA, et al. Warfarin use and the risk for stroke and bleeding in patients with atrial fibrillation undergoing dialysis. Circulation. 2014;129(11):1196-1203.
11. Carrero JJ, Evans M, Szummer K, et al. Warfarin, kidney dysfunction, and outcomes following acute myocardial infarction in patients with atrial fibrillation. JAMA. 2014;311(9):919-928.
12. Chan KE, Lazarus JM, Thadhani R, Hakim RM. Warfarin use associates with increased risk for stroke in hemodialysis patients with atrial fibrillation. J Am Soc Nephrol. 2009;20(10):2223-2233.
13. Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA. 2000;283(15):2008-2012.
14. Wakasugi M, Kazama JJ, Tokumoto A, et al. Association between warfarin use and incidence of ischemic stroke in Japanese hemodialysis patients with chronic sustained atrial fibrillation: a prospective cohort study. Clin Exp Nephrol. 2014;18(4):662-669.
15. Winkelmayer WC, Liu J, Setoguchi S, Choudhry NK. Effectiveness and safety of warfarin initiation in older hemodialysis patients with incident atrial fibrillation. Clin J Am Soc Nephrol. 2011;6(11): 2662-2668.
16. Wizemann V, Tong L, Satayathum S, et al. Atrial fibrillation in hemodialysis patients: clinical features and associations with anticoagulant therapy. Kidney Int. 2010; 77(12):1098-1106.
17. Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med. 1998;17: 2815-2834.
18. Freels S. Extracting summary statistics to perform meta-analysis of the published literature for survival endpoints. Stat Med. 2004;23(24):1817-1817.
19. Bonde AN, Lip GY, Kamper AL, et al. Net clinical benefit of antithrombotic therapy in patients with atrial fibrillation and chronic kidney disease: a nationwide observational cohort study. J Am Coll Cardiol. 2014;64(23):2471-2482.
20. Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions, Version 5.1.0. The Cochrane Collaboration. Available from www. cochrane-handbook.org.
21. Wells GA, Shea B, O'Connell D, et al. The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in Neta-Analyses. Ottawa, ON: Ottawa Hospital Research Institute; 2013.
22. Banerjee A, Fauchier L, Vourc'h P, et al. A prospective study of estimated glomerular filtration rate and outcomes in patients with atrial fibrillation: the Loire Valley Atrial Fibrillation Project. Chest. 2014;145(6):1370-1382.
23. Genovesi S, Rossi E, Gallieni M, et al. Warfarin use, mortality, bleeding and stroke in haemodialysis patients with atrial fibrillation. Nephrol Dial Transplant. 2015;30(3):491-498.
24. Chang CC, Liou HH, Wu CL, et al. Warfarin slows deterioration of renal function in elderly patients with chronic kidney disease and atrial fibrillation. Clin Interv Aging. 2013;8:523-529.
25. Chiu PF, Huang CH, Liou HH, et al. Lower-dose warfarin delays renal progression and prolongs patient survival in patients with stage 3-5 chronic kidney disease and nonvalvular atrial fibrillation: a 12-year follow-up study. Int J Clin Pharmacol Ther. 2014;52(8):504-508.
26. Lai HM, Aronow WS, Kalen P, et al. Incidence of thromboembolic stroke and of major bleeding in patients with atrial fibrillation and chronic kidney disease treated with and without warfarin. Int J Nephrol Renovasc Dis. 2009;2:33-37.
27. Abbott KC, Trespalacios FC, Taylor AJ, Agodoa LY. Atrial fibrillation in chronic dialysis patients in the United States: risk factors for hospitalization and mortality. BMC Nephrol. 2003;4:1.
28. Providencia R, Marijon E, Boveda S, et al. Meta-analysis of the influence of chronic kidney disease on the risk of thromboembolism among patients with nonvalvular atrial fibrillation. Am J Cardiol. 2014;114(4):646-653.
29. AdamsMJ, Irish AB, Watts GF, Oostryck R, Dogra GK. Hypercoagulability in chronic kidney disease is associatedwith coagulation activation but not endothelial function. Thromb Res. 2008;123(2):374-380.
30. Vazquez E, Sanchez-Perales C, Garcia-Cortes MJ, et al. Ought dialysis patients with atrial fibrillation be treated with oral anticoagulants? Int J Cardiol. 2003; 87(2-3):135-139; discussion 139-141.
31. January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2014;64(21):e1-e76.
32. Guyatt GH, Norris SL, Schulman S, et al. Methodology for the development of antithrombotic therapy and prevention of thrombosis guidelines: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):53S-70S.
33. Chan KE, Edelman ER, Wenger JB, Thadhani RI, Maddux FW. Dabigatran and rivaroxaban use in atrial fibrillation patients on hemodialysis. Circulation. 2015;131(11):972-979.
34. WeydeW, Letachowicz W, Krajewska M, et al. Native forearm fistulas utilizing the basilic vein: an underused type of vascular access. J Nephrol. 2008;21(3):363-367.
35. Lega JC, Bertoletti L, Gremillet C, et al. Consistency of safety and efficacy of new oral anticoagulants across subgroups of patients with atrial fibrillation. PLoS One. 2014;9(3):e91398.
36. Bousser MG, Bouthier J, Buller HR, et al. Comparison of idraparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: a randomised, open-label, non-inferiority trial. Lancet. 2008;371(9609):315-321.